{"id":697138,"date":"2024-05-01T17:56:02","date_gmt":"2024-05-01T17:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=697138"},"modified":"2024-05-01T17:56:02","modified_gmt":"2024-05-01T17:56:02","slug":"atopic-dermatitis-market-to-witness-an-upsurge-in-growth-by-2032-examines-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/atopic-dermatitis-market-to-witness-an-upsurge-in-growth-by-2032-examines-delveinsight_697138.html","title":{"rendered":"Atopic Dermatitis Market to Witness an Upsurge in Growth by 2032, Examines DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1714547863.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Atopic Dermatitis Market to Witness an Upsurge in Growth by 2032, Examines DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1714547863.jpeg\" alt=\"Atopic Dermatitis Market to Witness an Upsurge in Growth by 2032, Examines DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>&ldquo;Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast &ndash; 2032&rdquo;<\/strong>&nbsp;report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Atopic Dermatitis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent cases of Atopic Dermatitis in the United States were around 32,573,900 cases in 2022.<\/li>\n<li>The US contributed to the largest prevalent population of Atopic Dermatitis, acquiring ~45% of the 7MM in 2022.<\/li>\n<li>The increase in Atopic Dermatitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.<\/li>\n<li>As per DelveInsight analysis, the Atopic Dermatitis Market is anticipated to witness growth at a considerable CAGR.<\/li>\n<li>The leading Atopic Dermatitis Companies working in the market include Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.<\/li>\n<li>Promising Atopic Dermatitis Therapies in the various stages of development include Dupilumab, Apremilast, EDP1815, BMS-986166, Branebrutinib, Tofacitinib ointment 20mg\/g, MEDI3506, Lebrikizumab, and others.<\/li>\n<li>April 2024:- Eli Lilly and Company- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis.<\/li>\n<li>March 2024: AbbVie- The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover which therapies are expected to grab the Atopic Dermatitis Market Share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Dermatitis Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Overview<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;Atopic dermatitis, often referred to simply as eczema, is a chronic skin condition characterized by inflammation, itching, and redness. It commonly appears as dry, itchy patches on the skin, which can become scaly, crusty, or oozing when scratched. Atopic dermatitis is believed to result from a combination of genetic, environmental, and immune system factors. It often occurs in individuals with a personal or family history of allergic conditions such as asthma or hay fever. While there is no cure for atopic dermatitis, various treatments such as moisturizers, topical steroids, and antihistamines can help manage symptoms and reduce flare-ups.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Epidemiology Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section of Atopic Dermatitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Atopic Dermatitis Prevalent Cases by Age<\/li>\n<li>Total Atopic Dermatitis Diagnosed Cases<\/li>\n<li>Total Atopic Dermatitis Treated Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Atopic Dermatitis Epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Dermatitis Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Drugs Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The Atopic Dermatitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Atopic Dermatitis signaling in Atopic Dermatitis are likely to uncover new therapeutic targets and further expand treatment options for patients.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Treatment Market Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The Atopic Dermatitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Atopic Dermatitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To learn more about Atopic Dermatitis treatment guidelines, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Dermatitis Treatment Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">The report&#8217;s outlook on the Atopic Dermatitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Atopic Dermatitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Atopic Dermatitis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion\/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Atopic Dermatitis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Drugs Uptake<\/strong><\/p>\n<p style=\"text-align: justify;\">The drug chapter of the Atopic Dermatitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Atopic Dermatitis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Atopic Dermatitis Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Several Atopic Dermatitis Companies working in the market include Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the FDA-approved drugs for Atopic Dermatitis @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Atopic Dermatitis Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Atopic Dermatitis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Atopic Dermatitis Companies- Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.<\/li>\n<li>Atopic Dermatitis Therapies- Dupilumab, Apremilast, EDP1815, BMS-986166, Branebrutinib, Tofacitinib ointment 20mg\/g, MEDI3506, Lebrikizumab, and others.<\/li>\n<li>Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers<\/li>\n<li>Atopic Dermatitis Market Access and Reimbursement, Unmet Needs and Future Perspectives<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about Atopic Dermatitis Drugs in development @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Dermatitis Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Atopic Dermatitis (AD) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">5. Executive Summary<\/p>\n<p style=\"text-align: justify;\">6. Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Patient Journey<\/p>\n<p style=\"text-align: justify;\">9. Key Endpoints in Atopic Dermatitis Clinical Trials<\/p>\n<p style=\"text-align: justify;\">10. Marketed Therapies<\/p>\n<p style=\"text-align: justify;\">11. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis<\/p>\n<p style=\"text-align: justify;\">13. Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">14. KOL Views<\/p>\n<p style=\"text-align: justify;\">15. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">16. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">19. Disclaimer<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=atopic-dermatitis-market-to-witness-an-upsurge-in-growth-by-2032-examines-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=atopic-dermatitis-market-to-witness-an-upsurge-in-growth-by-2032-examines-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s&nbsp;&ldquo;Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast &ndash; 2032&rdquo;&nbsp;report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/atopic-dermatitis-market-to-witness-an-upsurge-in-growth-by-2032-examines-delveinsight_697138.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-697138","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/697138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=697138"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/697138\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=697138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=697138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=697138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}